VSV-GP154
- Generic Name
- VSV-GP154
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
Phase 1
Recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Amal Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT05846516
- Locations
- 🇺🇸
USC/Norris Comprehensive Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath